A Phase 3, Multicenter, Open-Label, Long-Term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
Latest Information Update: 18 Sep 2024
At a glance
- Drugs Efgartigimod alfa (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions; Registrational
- Acronyms ADVANCE SC+
- Sponsors argenx
- 09 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 16 Aug 2023 This trial has been discontinued in Ireland.
- 19 Dec 2022 The trial has been completed in Denmark, according to European Clinical Trials Database record.